Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination with Targeted and Endocrine Therapies in Participants with Advanced Breast Cancer and As a Single Agent in Advanced Solid Tumors

Next Previous
Search
Trial Profile

A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination with Targeted and Endocrine Therapies in Participants with Advanced Breast Cancer and As a Single Agent in Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary) ; RLY-5836 (Primary)
  • Indications Advanced breast cancer; Breast cancer; HER2 negative breast cancer; Male breast cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Relay Therapeutics

    • Most Recent Events

    • 07 Mar 2025 Planned End Date changed from 25 Jul 2024 to 28 May 2025.
    • 07 Mar 2025 Planned primary completion date changed from 22 Jun 2024 to 7 Mar 2025.
    • 17 Feb 2024 Planned End Date changed from 13 Jan 2026 to 25 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top